AIMS/HYPOTHESIS: The regulation of glucagon secretion from alpha cells is poorly understood. Since action potential firing at low glucose is required for glucagon secretion, we hypothesised that voltage-dependent K(+) (Kv) currents limit glucagon secretion under these conditions, similarly to their role in insulin secretion. METHODS: Kv currents and action potential firing of mouse and human alpha cells, identified by immunostaining, were examined by whole-cell patch-clamp. Glucagon secretion from mouse and human islets was measured by ELISA. RESULTS: Kv current density was 35% larger in alpha than in beta cells. Alpha cell Kv channels were sensitive to block by tetraethylammonium (TEA) and 4-aminopyridine. Surprisingly, Kv channel inhibition reduced glucagon release to the same extent as glucose. Robust action potential firing was observed in beta cells when ATP-sensitive K(+) channels were closed, but in alpha cells a negative current (-8 pA) injection was required for action potential firing. TEA (0.5 mmol/l) impaired alpha cell action potential firing, which could be restored by further hyperpolarising current injection (-16 pA). Kv currents were more sensitive to the Kv2 inhibitor stromatoxin (100 nmol/l) in mouse (80%) than in human (45%) alpha cells. Finally, the maxi-K (BK) channel inhibitor iberiotoxin (100 nmol/l) blocked 55% of the current in human alpha cells and inhibited glucagon release from human islets. CONCLUSIONS/ INTERPRETATION: Kv currents in alpha cells are positive regulators of glucagon secretion. These currents, mediated by Kv2 and BK channels, limit membrane depolarisation, and prevent inactivation of alpha cell action potentials and suppression of glucagon release.
AIMS/HYPOTHESIS: The regulation of glucagon secretion from alpha cells is poorly understood. Since action potential firing at low glucose is required for glucagon secretion, we hypothesised that voltage-dependent K(+) (Kv) currents limit glucagon secretion under these conditions, similarly to their role in insulin secretion. METHODS: Kv currents and action potential firing of mouse and human alpha cells, identified by immunostaining, were examined by whole-cell patch-clamp. Glucagon secretion from mouse and human islets was measured by ELISA. RESULTS: Kv current density was 35% larger in alpha than in beta cells. Alpha cell Kv channels were sensitive to block by tetraethylammonium (TEA) and 4-aminopyridine. Surprisingly, Kv channel inhibition reduced glucagon release to the same extent as glucose. Robust action potential firing was observed in beta cells when ATP-sensitive K(+) channels were closed, but in alpha cells a negative current (-8 pA) injection was required for action potential firing. TEA (0.5 mmol/l) impaired alpha cell action potential firing, which could be restored by further hyperpolarising current injection (-16 pA). Kv currents were more sensitive to the Kv2 inhibitor stromatoxin (100 nmol/l) in mouse (80%) than in human (45%) alpha cells. Finally, the maxi-K (BK) channel inhibitor iberiotoxin (100 nmol/l) blocked 55% of the current in human alpha cells and inhibited glucagon release from human islets. CONCLUSIONS/ INTERPRETATION: Kv currents in alpha cells are positive regulators of glucagon secretion. These currents, mediated by Kv2 and BK channels, limit membrane depolarisation, and prevent inactivation of alpha cell action potentials and suppression of glucagon release.
Authors: James Herrington; Manuel Sanchez; Denize Wunderler; Lizhen Yan; Randal M Bugianesi; Ivy E Dick; Sam A Clark; Richard M Brochu; Birgit T Priest; Martin G Kohler; Owen B McManus Journal: J Physiol Date: 2005-06-02 Impact factor: 5.182
Authors: David A Jacobson; Andrey Kuznetsov; James P Lopez; Shera Kash; Carina E Ammälä; Louis H Philipson Journal: Cell Metab Date: 2007-09 Impact factor: 27.287
Authors: Yuk M Leung; Ishtiaq Ahmed; Laura Sheu; Robert G Tsushima; Nicholas E Diamant; Manami Hara; Herbert Y Gaisano Journal: Endocrinology Date: 2005-08-18 Impact factor: 4.736
Authors: Matthias Braun; Reshma Ramracheya; Martin Bengtsson; Quan Zhang; Jovita Karanauskaite; Chris Partridge; Paul R Johnson; Patrik Rorsman Journal: Diabetes Date: 2008-04-04 Impact factor: 9.461
Authors: C L Basford; K J Prentice; A B Hardy; F Sarangi; S J Micallef; X Li; Q Guo; A G Elefanty; E G Stanley; G Keller; E M Allister; M C Nostro; M B Wheeler Journal: Diabetologia Date: 2011-11-11 Impact factor: 10.122
Authors: Accalia Fu; Karine Robitaille; Brandon Faubert; Courtney Reeks; Xiao-Qing Dai; Alexandre B Hardy; Krishana S Sankar; Svetlana Ogrel; Osama Y Al-Dirbashi; Jonathan V Rocheleau; Michael B Wheeler; Patrick E MacDonald; Russell Jones; Robert A Screaton Journal: Diabetologia Date: 2015-04-16 Impact factor: 10.122
Authors: Nadejda Bozadjieva; Manuel Blandino-Rosano; Jennifer Chase; Xiao-Qing Dai; Kelsey Cummings; Jennifer Gimeno; Danielle Dean; Alvin C Powers; George K Gittes; Markus A Rüegg; Michael N Hall; Patrick E MacDonald; Ernesto Bernal-Mizrachi Journal: J Clin Invest Date: 2017-11-06 Impact factor: 14.808
Authors: Matthew T Dickerson; Prasanna K Dadi; Molly K Altman; Kenneth R Verlage; Ariel S Thorson; Kelli L Jordan; Nicholas C Vierra; Gautami Amarnath; David A Jacobson Journal: Am J Physiol Endocrinol Metab Date: 2019-01-29 Impact factor: 4.310
Authors: Mourad Ferdaoussi; Xiaoqing Dai; Mette V Jensen; Runsheng Wang; Brett S Peterson; Chao Huang; Olga Ilkayeva; Nancy Smith; Nathanael Miller; Catherine Hajmrle; Aliya F Spigelman; Robert C Wright; Gregory Plummer; Kunimasa Suzuki; James P Mackay; Martijn van de Bunt; Anna L Gloyn; Terence E Ryan; Lisa D Norquay; M Julia Brosnan; Jeff K Trimmer; Timothy P Rolph; Richard G Kibbey; Jocelyn E Manning Fox; William F Colmers; Orian S Shirihai; P Darrell Neufer; Edward T H Yeh; Christopher B Newgard; Patrick E MacDonald Journal: J Clin Invest Date: 2015-09-21 Impact factor: 14.808